MedPath

Comparison of the Botulinum toxin type A with oral Tizanidine in the treatment of spasticity due to stroke

Not Applicable
Conditions
Spasticity due to cerebral stroke.
Sequelae of cerebral infarction
Registration Number
IRCT2012112411563N1
Lead Sponsor
Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
68
Inclusion Criteria

(to have a history of cerebral stroke for at least 3 months ago; severity of spasticity more than 2 in Ashworth scale; to be older than 35 years old)
Exclusion criteria: (patients with impairment in level or content of consciousness; to have systemic disorders such as Diabetes, hyperthyroidism, electrolyte disorders, renal failure; to be older than 70 years old)

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
imbs Spasticity. Timepoint: in the start of the study for all the patients, week 16 (for Tizanidine) and 3 months after the last injection (for Botulinum). Method of measurement: Based on Ashworth scale.;Limb functional improvement. Timepoint: in the start of the study for all the patients, week 16 (for Tizanidine) and 3 months after the last injection (for Botulinum). Method of measurement: Based on ARAT scale.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath